Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + GS chemotherapy as first-line treatment for unresectable advanced pancreatic cancer
ChiCTR2500095693Phase 2Not yet recruiting
- Sponsor
- Sichuan Cancer Hospital
- Start
- Jan 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab, gemcitabine and tegafur in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by Sichuan Cancer Hospital. Primary endpoint: Objective response rate. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
cadonilimabgemcitabinetegafur
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500095693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500095693.